Format

Send to

Choose Destination
Lancet. 2000 Mar 18;355(9208):1008-10.

Thiazolidinediones: an update.

Author information

1
Institut de Génétique et Biologie Moleculaire et Cellulaire, Illkirch, France.

Abstract

Thiazolidinediones, which are being developed for the treatment of insulin resistance and type 2 diabetes mellitus, bind and activate peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates the expression of several genes involved in metabolism. This receptor controls adipocyte differentation, lipid storage, and insulin sensitisation. Besides metabolic activities, thiazolidinediones have effects as diverse as the control of host defence, cell proliferation, and tumorigenesis.

Comment in

PMID:
10768450
DOI:
10.1016/S0140-6736(00)90002-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center